Skip to content

The locally recurrent rectal cancer quality of life study

Health-related Quality of Life and survivorship in Locally Recurrent Rectal Cancer. The LRRC-QoL study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN13692671
Enrollment
320
Registered
2021-12-20
Start date
2020-11-05
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health-related quality of life and survivorship in locally recurrent rectal cancer Cancer

Interventions

The study has been designed as an international, multi-centre, mixed methods study. The study consists of 3 workstreams. The first workstream will adapt the LRRC-QoL into a number of languages and fo

Sponsors

University of Leeds
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: Workstream I: 1.1 Aged over or equal to 18 years 1.2 Radiological and/or histological diagnosis of locally recurrent rectal cancer 1.3 Undergone treatment for locally recurrent rectal cancer within the last 2 years 1.4 Able to provide informed written consent to participate 1.5 Able to read and write in the target language. Workstream II: 2.1 Aged over or equal to 18 years 2.2 New radiological and/or histological diagnosis of locally recurrent rectal cancer 2.3 Able to provide informed written consent to participate 2.4 Able to read and write in the target language. Workstream III: 3.1 Aged over or equal to 18 years 3.2 Treated for locally recurrent rectal cancer and are disease-free for more than 3 years 3.3 Able to provide informed written consent to participate 3.4 Able to read and write in the target language

Exclusion criteria

Exclusion criteria: 1. Patients with cognitive impairment 2. Patients who are in remission from treatment of primary rectal cancer with no evidence of local recurrence 3. Patients who are receiving treatment for distant metastatic disease following previous treatment of rectal cancer with no evidence of local recurrence

Design outcomes

Primary

MeasureTime frame
Health-related quality of life assessed using the LRRC-QoL questionnaire at baseline, 10 - 14 days, 3, 6 and 12 months.

Secondary

MeasureTime frame
The survivorship issues relevant to patients who have undergone treatment for locally recurrent rectal cancer, these will be established through using qualitative interviews at a single time point.

Countries

Australia, Brazil, Canada, Denmark, England, France, India, Ireland, Italy, Netherlands, New Zealand, Pakistan, Russian Federation, Scotland, Singapore, Spain, Sweden, United Kingdom, United States of America, Wales

Contacts

Public ContactNiamh McKigney
N.McKigney@leeds.ac.uk+44 1133438089

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 9, 2026